HIMS Form 144: Melissa Baird to sell 33,333 Class A shares via Goldman Sachs
Rhea-AI Filing Summary
Hims & Hers Health insider Melissa Baird filed a Form 144 notifying a proposed sale of 33,333 Class A common shares through Goldman Sachs & Co. LLC, with an aggregate market value of $1,598,650.68. The filing states the shares were acquired on 05/13/2020 as compensation via stock options and that the planned payment method is a cashless exercise/same-day sale. The document lists 217,641,958 shares outstanding for the class and discloses multiple individual sales by Ms. Baird during May–July 2025 with specific dates, share amounts and gross proceeds. No earnings, guidance or other corporate actions are included in this filing.
Positive
- None.
Negative
- The filing discloses a proposed insider sale of 33,333 Class A shares valued at $1,598,650.68 to be executed through Goldman Sachs & Co. LLC.
- The notice lists multiple individual sales by Melissa Baird during May–July 2025 with dates, share amounts and gross proceeds, indicating ongoing insider disposition of shares.
Insights
TL;DR: Insider Melissa Baird plans a Form 144 sale of 33,333 HIMS shares; transactions are disclosures of personal trading, not corporate news.
The filing notifies a planned sale of 33,333 Class A shares through Goldman Sachs with an aggregate market value of $1,598,650.68. These shares were acquired as compensation on 05/13/2020 via stock options and will be sold following a cashless exercise/same-day sale process. The form also itemizes multiple individual sales by the same person across May–July 2025, each with date, share amount and gross proceeds. From a market-impact perspective, this is an insider trading disclosure required by securities rules; it does not report operational or financial performance metrics for the company.
TL;DR: The filing shows routine Rule 144 compliance and an attestation regarding nonpublic material information; it is a disclosure, not a policy change.
The filer attests they are not aware of undisclosed material adverse information and provides transaction provenance (acquired as compensation; cashless exercise). The broker listed is Goldman Sachs & Co. LLC and the planned sale date is shown as 08/12/2025. The form includes detailed historical sales by the same person over the prior months. There is no indication in the filing of a trading plan adoption date or other corporate governance actions; the submission is a regulatory notice to disclose intended insider sales under Rule 144.